A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells

Published:2014-11-03 Issue:32 Volume:34 Page:4199-4210
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Thrane S,Pedersen A M,Thomsen M B H,Kirkegaard T,Rasmussen B B,Duun-Henriksen A K,Lænkholm A V,Bak M,Lykkesfeldt A E,Yde C W

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/onc2014351.pdf

Reference57 articles.

1. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771–784.

2. Howell A, Osborne CK, Morris C, Wakeling AE . ICI 182 780 (Faslodex): development of a novel, ‘pure’ antiestrogen. Cancer 2000; 89: 817–825.

3. Palmieri C, Patten DK, Januszewski A, Zucchini G, Howell SJ . Breast cancer: current and future endocrine therapies. Mol Cell Endocrinol 2013; 382: 695–723.

4. Musgrove EA, Sutherland RL . Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9: 631–643.

5. Nahta R, O'Regan RM . Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers. Breast Cancer Res Treat 2012; 135: 39–48.

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Seize the engine: Emerging cell cycle targets in breast cancer;Clinical and Translational Medicine;2024-01

2. Discovery of potential RSK1 inhibitors for cancer therapy using virtual screening, molecular docking, molecular dynamics simulation, and MM/GBSA calculations;Journal of Biomolecular Structure and Dynamics;2023-12-12

3. Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer;npj Breast Cancer;2023-09-08

4. Targeting MCL-1 protein to treat cancer: opportunities and challenges;Frontiers in Oncology;2023-07-31

5. Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer;JAMA Oncology;2023-06-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3